Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis

Rheumatology

Volumn 45, Issue 12, 2006, Pages 1455-1457

  Distler, Oliver ^a   Behrens, F ^b   Huscher, D ^c   Foeldvari, I ^d   Zink, A ^c   Nash, P ^e   Denton, C P ^f   Humbert, M ^g   Matucci Cerinic, M ^h   Seibold, J ⁱ   Rubin, L ^j   Furst, D E ^k  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b GOETHE UNIVERSITY   (Germany)

^c German Natl Research Cent for   (Germany)

^d Klinikum Eilbek   (Germany)

^e Rheumatology Research Unit   (Australia)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g HÔPITAL ANTOINE BÉCLÈRE   (France)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; ILOPROST; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST;

CLINICAL TRIAL; DISEASE COURSE; DRUG RESPONSE; EDITORIAL; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUESTIONNAIRE; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

ANTIHYPERTENSIVE AGENTS; DELPHI TECHNIQUE; HUMANS; HYPERTENSION, PULMONARY; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 33749015524     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel273     Document Type: Editorial

References (25)

1. Galie N, Torbicki A, Barst R et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
2. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
3. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hamodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-50.
4. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
5. Simonneau G, Barst RJ, Gabe N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800-4.
6. Galie N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502.
7. Barst RJ, McGoon M, McLaughlin V et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:2119-25.
8. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
9. Channick R, Badesch DB, Tapson VF et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: A placebo-controlled study. J Heart Lung Transplant 2001;20:262-3.
10. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
11. Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.
12. Galie N, Badesch D, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35.
13. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
14. Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S):81S-8S.
15. Hoeper MM, Oudiz RJ, Peacock A et al. End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives. J Am Coll Cardiol 2004;43(12 Suppl S):48S-55S.
16. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25:198-9.
17. Bellamy N. Clinimetric concepts in outcome assessment: The OMERACT filter. J Rheumatol 1999;26:948-50.
18. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630-47.
19. Linstone H, Turoff M. The Delphi Method. Techniques and Applications: New Jersey Institute of Technology, CA, USA; 2002.
20. Roth R, Wood W. A Delphi approach to acquiring knowledge from single and multiple experts. In: Trends and Direction in Expert Systems Proceedings of the 1990 ACM SIGBDP conference on trends and directions in expert systems. Orlando, FL, United States, 1990; 301-324.
21. Young B, Linstone HA. Delphi Method. In: Olsen, SA, (Ed.) Group Planning and Problem-Solving. Methods in Engineering Management, John Wiley & Sons, New York, NY, USA 1982;103-154.
22. McKee M, Priest P, Ginzler M, Black N. How representative are members of expert panels? Quality Ass Health Care 1991;3:89-94.
23. Zochling J, van der Heijde D, Burgos-Vargas R et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
24. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64(Suppl 2):iI49-54.
25. Jones J, Hunter D. Consensus methods for medical and health services research. Br Med J 1995;311:376-80.